Adverse effects of thyroid hormone preparations and antithyroid drugs

Drug Safety

Volumn 15, Issue 1, 1996, Pages 53-63

  Bartalena, Luigi ^a   Bogazzi, Fausto ^a   Martino, Enio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; AUTOANTIBODY; CARBIMAZOLE; GLUCAGON ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; LIOTHYRONINE; LITHIUM CARBONATE; POTASSIUM PERCHLORATE; PROPYLTHIOURACIL; THIAMAZOLE; THIONAMIDE; THYROID HORMONE; THYROXINE; THYROXINE I 131;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; APLASTIC ANEMIA; BONE ATROPHY; CARDIOVASCULAR DISEASE; CHILD; COLLAGEN DISEASE; DIARRHEA; DRUG ERUPTION; DRUG INTOXICATION; DRUG MONITORING; DRUG SAFETY; FATIGUE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; LUPUS ERYTHEMATOSUS; NAUSEA; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PRURITUS; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TASTE DISORDER; THROMBOCYTE DISORDER; THROMBOCYTOPENIA; UVEITIS; VASCULITIS; VOMITING;

EID: 0029990705     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199615010-00004     Document Type: Review

References (98)

1. Kaufman SC, Gross GP, Kennedy DL. Thyroid hormone use: trends in the United States from 1960 through 1988. Thyroid 1988; 1: 285-91
2. Petersen K, Bengtsson C, Lapidus L, et al. Morbidity, mortality, and quality of life for patients treated with levothyroxine. Arch Intern Med 1990; 150: 2077-81
3. Istituto Nazionale della Nutrizione. Alimentazione e nutrizione in Italia: aspetti, problemi, proposte. Rome 1992
4. Toft AD. Thyroxine therapy. N Engl J Med 1994; 331: 174-80
5. Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 1993; 119: 492-502
6. Smith SA, Gharib H. Clinical use of thyroid hormone. Adv Endocrinol Metab 1994; 5: 323-48
7. Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA 1995; 273: 808-12
8. Nystrom E, Caidahl K, Fager G, et al. A double-blind, cross-over 12-month study of L-thyroxine treatment of women with 'subclinical' hypothyroidism. Clin Endocrinol (Oxf) 1988; 29: 63-75
9. Roti E, Minelli R, Gardini E, et al. The use and misuse of thyroid hormone. Endocr Rev 1993; 14: 401-23
10. Bartalena L, Pinchera A. Levothyroxine suppressive therapy: harmful and useless or harmless and useful? J Endocrinol Invest 1994; 17: 675-7
11. Bartalena L, Pinchera A. Effects of thyroxine excess on peripheral organs. Acta Med Austr 1994; 21: 60-5
12. Chiovato L, Santini F, Pinchera A. Treatment of hyperthyroidism. Thyroid Int 1995; 2: 1-22
13. Roti E, Minelli R, Gardini E, et al. Controversies in the treatment of thyrotoxicosis. Adv Endocrinol Metab 1994; 5: 429-60
14. Klein I, Becker DV, Levey GS. Treatment of hyperthyroid disease. Ann Intern Med 1994; 121: 281-8
15. Weetman AP. Graves' disease. In: Wheeler MH, Lazarus JH, editors. Diseases of the thyroid: pathophysiology and management. London: Chapman & Hall, 1994: 171-91
16. Braverman LE, Roti E. The role of iodine in the management of Graves' disease. Endocr Practice 1995; 1: 200-4
17. Cooper DS. Antithyroid drugs. N Engl J Med 1984; 311: 1353-62
18. Biondi B, Fazio S, Carella C, et al. Cardiac effects of long-term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993; 77: 334-8
19. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-6
20. Biondi B, Fazio S, Carella C, et al. Control of adrenergic over-activity by β-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1994; 78: 1028-33
21. Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992; 327: 94-8
22. Ladenson PW. Thyrotoxicosis and the heart: something old and something new. J Clin Endocrinol Metab 1993; 77: 332-3
23. Wartofsky L. Osteoporosis: a growing concern for the thyroidologist. Thyroid Today 1988; 11: 1-11
24. Baran DT, Braverman LE. Thyroid hormone and bone mass. J Clin Endocrinol Metab 1991; 72: 1182-3
25. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994; 130: 350-6
26. Marcocci C, Golia F, Bruno-Bossio G, et al. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab 1994; 78: 818-23
27. Leese GP, Jung RT, Guthrie C, et al. Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol (Oxf) 1992; 37: 500-3
28. Gow SW, Caldwell G, Toft AD, et al. Relationship between pituitary and other target organ responsiveness in hypothyroid patients receiving thyroxine replacement. J Clin Endocrinol Metab 1987; 64: 364-70
29. Bartalena L, Martino E, Pacchiarotti A, et al. Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients. J Clin Endocrinol Metab 1987; 64: 849-55
30. Cohen JH, Ingbar SH, Braverman LE. Thyrotoxicosis due to ingestion of excess thyroid hormone. Endocr Rev 1989; 10: 113-24
31. Hedberg CW, Janssen RS, Meyers B, et al. An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N Engl J Med 1987; 316: 993-7
32. Braunstein GD, Koblin R, Sugawara M, et al. Unintentional thyrotoxicosis factitia due to a diet pill. West J Med 1986; 145: 388-91
33. White JD, Litovitz TL. Levothyroxine poisoning. Pediatrics 1985; 75: 129-33
34. Locker GJ, Kotzmann H, Frev B, et al. Factitious hyperthyroidism causing acute myocardial infarction. Thyroid 1995; 5: 465-7
35. Bhasin S, Wallace W, Lawrence JB, et al. Sudden associated with thyroid hormone abuse. Am J Med 1981; 71: 887-9
36. Harvey RF. Thyroxine 'addicts'. BMJ 1973; 2: 35-8
37. Ohno F, Miyoshi K. Clinical observations on thyreoidismus medicamentosus due to weight reducing pills in Japan. Endocrinol Jpn 1971; 18: 321-6
38. Binimelis J, Bassas L, Marruecos L, et al. Massive thyroxine intoxication: evaluation of plasma extraction. Intensive Care Med 1987; 13: 33-8
39. Greer MA. Antithyroid drugs in the treatment of thyrotoxicosis. Thyroid Today 1980; 3: 1-5
40. Rosove MH. Agranulocytosis and antithyroid drugs. West J Med 1977; 126: 339-43
41. Retsagi R, Kelly JP, Kaufman DW and participants in the International Agranulocytosis and Aplastic Anaemia Study. Risk of agranulocytosis and aplastic anaemia in relation to use of antithyroid drugs. BMJ 1988; 297: 262-5
42. Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis associated with antithyroid drugs: effects of patient age and drug dose. Ann Intern Med 1983; 98: 26-9
43. Tamai H, Takaichi Y, Morita T, et al. Methimazole-induced agranulocytosis in Japanese patients with Graves' disease. Clin Endocrinol (Oxf) 1989; 30: 525-30
44. Meyer-Gessner M, Benker G, Lederbogen S, et al. Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature. J Endocrinol Invest 1994; 17: 29-36
45. Werner MC, Romaldini JH, Bromberg N, et al. Adverse effects related to thionamide drugs and their dose regimen. Am J Med Sci 1989; 297: 216-9
46. Tajiri J, Noguchi S, Murakami T, et al. Antithyroid drug-induced agranulocytosis. Arch Intern Med 1990; 150: 621-4
47. Schut NH, Wiersinga WM, Van Oers MH. Methimazole-induced agranulocytosis preceded by transient granulocytopenia: a case report. Neth J Med 1993; 43: 71-3
48. Fibbe WE, Claas FHJ, Van der Star-Dijkstra W, et al. Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells. Br J Haematol 1986; 64: 363-73
49. Toth EL, Mant MJ, Shivji S, et al. Propylthiouracil-induced agranulocytosis: an unusual presentation and a possible mechanism. Am J Med 1988; 85: 725-7
50. Wall JR, Fang SL, Kuroki T, et al. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis. J Clin Endocrinol Metab 1984; 58: 868-72
51. Hamada N, Itoh K, Momotani N, et al. Effect of corticosteroids in 10 cases of methimazole-induced agranulocytosjs. Endocrinol Jpn 1981; 28: 823-7
52. Tamai H, Mukuta T, Matsubayashi S, et al. Treatment of methimazole-induced agranulocytosis using recombinant human granulocyte colony-stimulating factor (rhG-CSF). J Clin Endocrinol Metab 1993; 77: 1356-60
53. Adorf D, Grajer KH, Kaboth W, et al. Agranulocytosis induced by antithyroid therapy: effects of treatment with granulocyte colony stimulating factor. Clin Invest 1994; 72: 390-2
54. Genet P, Pulik M, Lionnet F, et al. Agranulocytose aux antithyroidiens de synthèse: efficacité des facteurs de croissance hémutopoiétique. Ann Endocrinol (Paris) 1994; 55: 39-42
55. Magner JA, Snyder DK. Methimazole-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF). Thyroid 1994; 4: 295-6
56. Edell SL, Bartuska DG. Aplastic anemia secondary to methimazole: case report and review of hematologic side effect. J Am Med Wom Assoc 1975; 30: 412-3
57. Fewell RA, Engel EF, Zimmermann SL. Acute thrombopenic purpura associated with administration of propylthiouracil. JAMA 1950; 143: 891-2
58. Marchant B, Lees JFH, Alexander DW. Antithyroid drugs. Pharmacol Ther B 1978; 3: 305-48
59. Trotter WR. The relative toxicity of antithyroid drugs. J New Drugs 1962; 2: 333-43
60. Van Dijke CP, Heydendael RJ, De Kleine MJ. Methimazole, carbimazole, and congenital skin defects. Ann Intern Med 1987; 106: 60-1
61. Mandel SJ, Brent GA, Larsen PR. Review of antithyroid drug use during pregnancy and report of a case of aplasia cutis. Thyroid 1994; 4: 129-33
62. Frieden IJ. Aplasia cutis congenita: a clinical review and proposal for classification. Acta Dermatol 1986; 14: 646-60
63. Milham S, Elledge W. Maternal methimazole and congenital defects in children. Teratology 1972; 5: 125
64. Milham S. Scalp defects in infants of mothers treated for hyperthyroidism with methimazole or carbimazole during. pregnancy. Teratology 1985; 32: 321-5
65. Cooper DS. Which anti-thyroid drug? Am J Med 1986; 80: 1165-8
66. Wing DA, Millar LK, Koonings PP, et al. A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy. Am J Obstet Gynecol 1994; 170: 90-5
67. Vitug AC, Goldman JM. Hepatotoxicity from antithyroid drugs. Horm Res 1985; 21: 229-34
68. Liaw Y-F, Huang M-J, Fan K-D, et al. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. Ann Intern Med 1993; 118: 424-8
69. Blom H, Stolk J, Schreuder HB, et al. A case of carbimazole-induced intrahepatic cholestasis: an immune-mediated reaction? Arch Intern Med 1985; 145: 1513-5
70. Singh A, Thakur R. Scintigraphy study of propylthiouracil-induced submassive hepatic necrosis. Clin Nucl Med 1995; 20: 132-5
71. Arab DM, Malatjalian DA, Rittmaster RS. Severe cholestatic. jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 1995; 80: 1083-5
72. Mihas AA, Holley P, Koff RS, et al. Fulminant hepstitis and lymphocyte sensitization due to propylthiouracil. Gastroenterology 1976; 70: 770-4
73. Griswold WR, Mendoza SA, Johnston W, et al. Vasculitis associated with propylthiouracil. West J Med 1978; 128: 543-6
74. Vasily DB, Tyler WB. Propylthiouracil-induced cutaneous vasculitis: case presentation and review of the literature. JAMA 1980; 23: 458-61
75. Reidy TJ, Upshaw Jr JD, Chesney TM. Propylthiouracil-induced vasculitis: a fatal case. South Med J 1982; 75: 1297-8
76. Cassorla FG, Finegold DN, Parks JS, et al. Vasculitis, pulmonary cavitation, and anemia during antithyroid drug therapy. Am J Dis Child 1983; 137: 118-22
77. Amrhein JA, Kenny FM, Ross D. Granulocytopenia, lupus-like syndrome, and other complications of propylthiouracil therapy. J Pediatr 1970; 76: 54-63
78. Librik L, Sussman L, Bejar R, et al. Thyrotoxicosis and collagen-like disease in three sisters of American Indian extraction. J Pediatr 1970; 76: 64-8
79. Hung W, August GP. A 'collagen-like' syndrome associated with antithyroid therapy. J Pediatr 1973; 82: 852-4
80. Cetina JA, Fishbein E, Alarcòn-Segovia D. Antinuclear antibodies and propylthiouracil therapy [letter]. JAMA 1972; 220: 1012
81. Sato-Matsumura KC, Koizumi H, Matsumura T, et al. Lupus erythematosus-like syndrome induced by thiamazole and propylthiouracil. J Dermatol 1994; 21: 501-7
82. Reynolds LR, Bhathena D. Nephrotic syndrome associated with methimazole therapy. Arch Intern Med 1979; 139: 236-7
83. Ryan GB, Karnovsky MJ. An ultrastructural study of the mechanisms of proteinuria in aminonucleoside nephrosis. Kidney Int 1975; 8: 219-32
84. Hallman BL, Hurst JW. Loss of taste as toxic effect of methimazole (Tapazole) therapy: report of three cases [letter]. JAMA 1953; 152: 322
85. Brittebo EB. Metabolism-dependent toxicity of methimazole in the olfactory nasal mucosa. Pharmacol Toxicol 1995; 76: 76-9
86. Mikozami T, Okamura K, Kohno T, et al. Human T-lymphotropic virus type I-associated uveitis in patients with Graves' disease treated with methylmercaptoimidazole. J Clin Endocrinol Metab 1995; 80: 1904-7
87. Nakao K, Ohba N. Clinical features of HLTV-1 associated uveitis. Br J Ophthalmol 1993; 77: 274-9
88. Naeye RL, Terrien CM. Hemorrhagic state after therapy with propylthiouracil. Am J Clin Pharmacol 1960; 34: 254-7
89. Hirata Y, Tominaga M, Ito J-I, et al. Spontaneous hypoglycemia with insulin autoimmunity in Graves' disease. Ann Intern Med 1974; 81: 214-8
90. Hirata Y. Methimazole and insulin autoimmune syndrome with hypoglycemia. Lancet 1983; 2: 1037-8
91. Lu CC, Lee JK, Lam HC, et al. Insulin autoimmune syndrome in a patient with methimazole and carbimazole-treated Graves' disease: a case report. Chung Hua I Hsueh Tsa Chih (Taipei) 1994; 54: 353-8
92. Sanke T, Kondo M, Moriyama Y, et al. Glucagon binding auto-antibodies in a patient with hyperthyroidism treated with methimazole. J Clin Endocrinol Metab 1983; 57: 1140-4
93. Martino E, Aghini-Lombardi F, Mariotti S, et al. Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole. J Endocrinol Invest 1986; 9: 201-7
94. Barzilai D, Sheinfeld M. Fatal complications following the use of potassium perchlorate in thyrotoxicosis. Isr J Med Sci 1988; 2: 453-6
95. Temple R, Berman M, Carlson HE, et al. The use of lithium in Graves' disease. Mayo Clin Proc 1972; 47: 872-8
96. Schou M, Amdisen A, Trap-Jensen J. Lithium poisoning. Am J Psychiatry 1968; 125: 520-7
97. Martino E, Balzano S, Bartalena L, et al. Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism. J Endocrinol Invest 1991; 14: 847-51
98. Cooper DS. Treatment of thyrotoxicosis. In: Braverman LE, Utiger RD, editors. Werner's and Ingbar's the thyroid a fundamental and clinical text. 6th ed. Philadelphia: JB Lippincott Co., 1991: 887-916